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Introduction: The ongoing Corona Virus Pandemic is linked with high rates of morbidity and mortality globally. 
Early and effective predictors of clinical outcomes are urgently required to develop effective management 
protocols. 
Objective: To investigate the predictive efficacy of haematological biomarkers in COVID‐19 infection. 
Material and Methods: Blood samples were drawn from COVID‐19 infected pneumonia patients. Baseline 
clinical information was collected and quantification of the hemostatic variable was done.  Laboratory data both 
groups expired and recovered were compared using t-test, Mann Whitney- U test, chi squared-test, and Kruskal 
Wallis test. Multivariate regression analysis was performed to determine the independent contribution of the 
haematological variable in COVID‐19 related mortality. Receiver operating characteristic curves were drawn to 
find the predictive efficacy of significantly related parameters. 
Results: Out of 191 patients 68.1%  were male. D‐dimer (median 800 ng/mL; IQR 200‐3200) and NLR (median 
10.40; IQR 3.20-22.80) were found to be predominantly raised and significantly correlated with Covid mortality in 
multivariate regression analysis. The optimum cutoff value of D-dimer to predict in-hospital mortality was 450 
ng/ml with a sensitivity of 71.6% and a specificity of 95.8%. The optimum cut-off value of NLR to predict in-
hospital mortality was 5.450 with a sensitivity of 70.1% and a specificity of 71%. 
Conclusion: D-dimer and NLR could be used as the significant indicators in predicting the mortality of COVID-
19. 
Keywords: Predictive Efficacy, Haematological  Biomarkers, Covid -19 infection, D-dimer, NLR. 
 
424                                                                             Journal of Rawalpindi Medical College (JRMC); 2020; 24(4): 423-429  
Introduction 
 
Despite the preventive infection measures, COVID-19 
infection has taken on the proportions of pandemic 
around the globe. COVID-19 patients present with 
protean manifestations, from flu-like symptoms to 
multiple organ failure and death. Nearly 20% of 
patients, with COVID infection, become critically ill, 
with high mortality, ranging from 8% to 33%.1-3   
Excessive inflammation, platelet activation, 
endothelial dysfunction, hypercoagulability, and 
sepsis, along with many others, are held responsible 
for patho-physiological events in COVID infection. In-
turn, these translate into different findings, which 
predict the course and prognosis of the disease. In this 
regard, haematological findings are also of paramount 
importance.4,5    
Due to high morbidity and mortality, an early 
diagnosis of COVID infection is essential. The 
definitive diagnosis of this disease is made by a 
positive PCR test for the COVID antigen. Limited 
resources, insufficient training of the men's power, and 
many other confounding variables justify the 
identification of some inexpensive parameters which 
can reflect the presence of this disease. These, to a 
larger extent, can help manage the disease and can 
help differentiate severe from non-severe cases.6 
Standard guidelines for COVID-19 also give weightage 
to radiological, haematological, and biochemical 
parameters. Complete blood counts (CBC) are easily 
performed and inexpensive. Different parameters of  
CBC like, leucocyte count, absolute neutrophils, and 
lymphocytes count and their ratios are of importance 
in this regard.7-9  
Out of different pathogenetic mechanisms, underlying 
the severity of COVID infection, cytokine storm is now 
well established. Interleukin-6 (IL-6) is a key molecule 
in stimulating cytokine storm. 10 Criterias, clinical and 
diagnostic, are proposed to find out the risk of the 
cytokine storm. In lab tests, parameters reflecting 
inflammation, immune dysregulation, and 
hypercoagulability are of pivotal significance, in 
diagnosing cytokine storm. The majority of the 
patients (84), in cytokine storm, validate these 
criterias.11      
Haemostatic changes, observed in COVID patients, are 
detrimental in deciding the course and outcome of the 
COVID disease.2,12 Pulmonary complications and acute 
respiratory distress syndrome, seen in COVID, have a 
clear thrombo-embolic component.2  Endothelial cell 
infection can induce endothelial damage and 
dysfunction/activation, which in turn, triggers a 
coagulation cascade.2,13-19 
Deranged hematological parameters and haemostatis 
are commonly observed in the progression of the 
COVID infection.20,21 In this scenario speedy 
inexpensive laboratory testing can be helpful to 
provide clinicians with suitable information for 
rational medical resource allocation to reduce patient 
morbidity and mortality.22 Because of its severity, it 
would be valuable to explore risk factors of severity 
and mortality in patients with COVID-19 disease. It 
can help in adopting timely measures and 
interventions, to enhance the cure rate.23-25   
 
Materials and Methods 
 
This prospective study was performed in the 
Department of Pathology,  Benazir Bhutto  Hospital, 
Rawalpindi Medical University between June to 
August 2020. Patients were classified as mild, 
moderate, severe, or critically ill and followed up till 
the outcome (discharged or died) (Commission NH, 
2020). All COVID suspected patients had a clinical 
evaluation, blood tests, and  PCR test. Throat and 
nasopharyngeal samples were collected from all 
patients for COVID-19 viral nucleic acid detection via 
a real-time reverse transcription-polymerase chain 
reaction. Blood complete counts were performed on an 
automated haematology analyzer. Absolute 
neutrophils and lymphocyte counts were determined 
to calculate Neutrophil to Lymphocyte Ratio (NLR). 
Value of NLR more than 3 was considered significant. 
In coagulation profile, Prothrombin Time (PT), 
Activated Partial Thromboplastin Time (APTT) and D-
dimer was performed. D-dimer was measured on an 
automated chemistry analyzer, where immune 
complexes formed, between D-Dimer in the plasma 
and anti-human D-Dimer antibodies, in solution 
scatter light in proportion to their size, shape, and 
concentration. Turbidimeters measure the reduction of 
incident light due to reflection, absorption, or scatter. 
All statistical analyses were performed using the SPSS 
25 (SPSS Inc. Due to nonparametric distribution of 
data, results of continuous variables are given as 
median(interquartile range) and compared by using 
Mann–Whitney U test. Categorical variables are 
presented as number (percentage) and compared 
using the chi-squared test. Univariate and multivariate 
binary logistic regression analysis finds were 
performed. Receiver Operating Characteristic (ROC) 
curves were constructed to evaluate the sensitivity and 
specificity of age, D-dimer, and NLR in predicting 
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death. The area under the curve(AUC) was calculated, 
with higher values demonstrating better 
discriminatory ability. A p-value of <0.05 was 




A total of 191 RT-PCR confirmed COVID‐19 patients 
were analyzed. The mean age of the subjects was 49.83 
(SD 15.66) years, and 130 (68.1%) of the patients were 
male.  At the time of data lock, 124 (65.26%)subjects 
recovered to be discharged and 67 (35.1%) proceeded 
to death.  On presentation, 71 (37.2%) were classified 
as a mild group, 61 (38.8%) as a moderate group, and 
59 (32.8%) as severe. In the mild group, 4 (6.0%) 
proceeded to ICU and death; in the moderate group, 9 
(13.4%) developed the critical condition and died. In 
the severe group, 54 (80.6%) patients proceeded to 
death. Out of 67 diseased 37 were more than 60 years 
of age. Regarding haemostatic parameters, overall, 43 
(22.5%) patients had thrombocytopenia, 8 (4.2%) 
developed thrombocytosis, 83 (43.3%) had 
neutrophilia (Table 1). Compared with the recovered 
group, expired subjects were significantly older 60.22 ± 
14.44 versus 44.21 ± 13.28 years; (mean 
difference=16.01; t=7.51, 95% C.I., p-value=0.0001, 
P=0.001), had greater medians of D-dimer, PT, APTT, 
neutrophil count and NLR. Platelet count was lower in 
the expired group but the difference was not 
significant (Table 2). No significant difference was 
observed in the mortality rate in both genders 
(p=0.872). In Univariate analysis raised values of NLR, 
D-dimer, APTT, and PT showed a positive association 
with mortality (all P-value=0.0001). In Multivariate 
regression analysis after adjusting for all significantly 
associated variables in univariate regression analysis, 
age, odds ratio 95% CI; 1.13o (1.071, 1.194) D–dimer, 
OR, 95%CI; 1.007 (1.003, 1.010) NLR, OR, 95%CI; 1.342 
(1.095, 1.644) come out to be the significant predictors 
of mortality (all p-value=0.0001). 
Using recovered and died cases as the basis of positive 
division, the Receiver Operator Characteristics Curve 
Analyses for Age, peak D-dimer, PT, and NLR  were 
performed. It revealed D-dimer, age, and NLR as 
significant biomarkers (Figure 1; Table 3). The Area 
Under the ROC Curve (AUC) (0.902) for D-dimer was 
higher than that of age (0.788) and NLR (0.745). The 
optimum cutoff value of D-dimer to predict in-hospital 
mortality was 450 ng/ml with a sensitivity of 71.6% 
and a specificity of 95.8%. There were 54 patients with 
D-dimer ≥450 ng/ml and 137 with d-dimer up to 450 
ng/ml. The mortality rate for D-dimer ≥ 450 ng/ml 
group was significantly higher (88.9% vs 13.9) 
compared to D-dimer ≤ 450ng/ml (χ2=99.53; p-
value=0.0001). A cut-off value of age ≥52.5 years 
showed the optimum balance of sensitivity (70.1%) 
and specificity (71.0%). There were 83 patients ≥ 52.5 
years of age and 108 ≤ 52.5 years of age. The mortality 
rate of more than 52.5 years was greater than ≤ 52.5 
years (57.6% vs 17.6%; χ2=34.018; p-value=0.0001). 
Additionally, for NLR cutoff value of 5.45 showed the 
optimum balance of sensitivity (73.1%) and specificity 
(71.0%) (Table 4). 
 
Table 1: Clinical characteristics of Covid-19 patient 
Parameters Mild (n=75) Moderate (=59) Severe (n=57) Total (n=191) p-value 
Age 39.73 ± 10.50 51.46 ± 13.74 61.42 ± 14.66 49.83 ± 15.66 0.0001 
Sex% 46 (35.4%) 44 (33.8%) 40 (30.8%) 130 (68.1%) 0.663 
D-dimer 200 (200-600) 400 (200-800) 800 (200-3200) 200 (200-3200) 0.0001 
APTT 32 (32-54) 33 (32-46) 37 (32-82) 33 (32-82) 0.0001 
PT 14 (14-19) 14 (14-19) 16 (14-36) 14 (14-36) 0.0001 
Platelets# 198 (44-430) 269 (109-765) 200 (30-576) 209 (30-765) 0.002 
Neutrophils# 4.9 (1.80-9.50) 7.70 (2.30-15.60) 10.20 (3.20-22.80) 7.50 (1.80-22.80) 0.0001 
Lymphocytes# 1.60 (0.70-4.70) 1.30 (0.60-2.30) 1.50 (0.40-5.60) 1.50 (0.40-5.60) 0.010 
NLR* 3.00 (1.26-9.00) 5.65 (1.63-14.14) 6.77 (1.07-24.22) 5.03 (1.07-24.22) 0.0001 
Mortality % 4 (6.0%) 9 (13.4%) 54 (80.6%) 67 (35.1%) 0.0001 
*NLR=Neutrophil to Lymphocytes Ration; Age; One way ANOVA, Sex and Mortality; Chi-Square Test; 
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D-dimer (ng/ml) 125-250 200 (200-800) 800 (200-3200) 0.0001 
APTT (Secs) 21-32 32 (32-48) 36 (32-82) 0.0001 
PT (secs) 9.8-14 sec 14 (14-26) 16 (14-36) 0.0001 
Platelets cmm2 150-450 215 (44-765) 205 (30-576) 0.182 
Neutrophils count (absolute) 1.7-7.9 5.65 (1.80-19.50) 10.20 (3.20-22.80) 0.0001 
Lymphocytes count (absolute) 1.0-4.8 1.60 (0.60-4.70) 1.50 (0.40-5.60) 0.788 
NLR Upto 3 4.29 (1.26- 14.14)  6.77 (1.07-24.22) 0.0001 
Mann Whiteny U-test; Data shown as median (minimum-maximum).                   
 
Figure 1: Receiver Operator Characteristics (ROC) Curve Analyses 
 
Table 3: Association of haematological parameters with critical illness and mortality in Covid infection 
 Univariate Regression Analysis                  Multivariate Regression Analysis 
Variables OR (95%CI) P-value OR (95%CI) P-value 
Age 1.087 (1.058, 1.117) 0.0001 1.130 (1.071, 1.194) 0.0001* 
Sex 1.161 (.610, 2.209) 0.897   
D-dimer 1.008 (1.005, 1.010) 0.0001 1.007 (1.003, 1.010) 0.0001* 
APTT 1.164 (1.085, 1.249) 0.0001 1.005 (0.870, 1.162) 0.941 
PT 2.000 (1.5849, 2.525) 0.0001 1.457 (0.942, 2.256) 0.091 
NLR 1.339(1.203, 1.491) 0.0001 1.342 (1.095, 1.644) 0.005* 
Platelets 0.998 (0.996, 1.001) 0.240   
 
Table 4: Area under the ROC curve analysis 
Parameters AUC (95%CI) Cuttoff-value Sensitivity Specificity p-value 
Age 0.788 (0.720-0.856 52.5 years 70.1% 71.0% 0.0001 
D-Dimer 0.902 (0.851-0.952) 550 ng/ml 71.6% 96.0% 0.0001 
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Discussion 
 
The present study showed that besides age, 
haematological parameters including, NLR, D-dimer 
are significant predictors of disease severity and 
mortality.  Results of raised D-Dimer levels, in the 
present study,  are consistent with different studies 
that showed higher D-Dimer levels in expired COVID-
19  patients compared to survive.17,26-30 Elevated D- 
dimer level is a risk factor for the development of DVT 
or pulmonary embolism and can predict both severity 
and mortality.2,31,32 British Thoracic Society, based on 
risk stratification, suggested prophylactic low dose 
heparin in COVID patients with D-dimer more than 
3000 ng/ml, while D-dimer more than 1000 ng/ml is 
an independent risk factor for the critical disease.4,14,33   
SARS-CoV2 infects type–II pneumonocytes via 
angiotensin-converting enzyme 2 (ACE 2) receptors. 
These, in–turn, triggers the phenomenon culminating 
in a characteristic Pulmonary Intravascular 
Coagulation (PIC).34 Cytokine storm, increased 
expression of tissue factor on endothelium, and 
excessive recruitment of neutrophils and 
macrophages, all potentiate intrapulmonary activation 
of coagulation. Thrombosis observed is primarily 
intrapulmonary, but can proceed to systemic 
thrombosis in a subset of patients. This 
hypercoagulability may be attributed to endothelial 
dysfunction, elevated circulating platelet 
microparticles, neutrophil extracellular traps (NATs), 
and elevated inflammatory cytokines.18,24,29,35,36  
Resistance to fibrinolysis could be an additional 
underlying mechanism to the hypercoagulable state 
that predisposes to thrombosis.37 Majority of the 
patients with COVID-19 infection show high levels of 
a pro-inflammatory cytokine, IL-6. IL-6 induces tissue 
factor gene expression in endothelial cells and 
monocytes, fibrinogen synthesis, and platelet 
production.10  
 Markedly increased D-dimers, increased fibrinogen, 
unusual anaemia and haemolysis, unpronounced  
PT/APTT prolongation, mild thrombocytopenia, 
uncommon bleeding, marked pulmonary involvement 
and evident thrombosis are characteristic findings in 
COVID coagulopathy. As compared to it, DIC is 
characterized by a moderate increase in D-dimers, 
decreased fibrinogen, evident anaemia and 
haemolysis, pronounced prolongation of PT/APTT, 
severe thrombocytopenia, unusual thrombosis, 
prominent bleeding, and mild pulmonary 
involvement.12,28,39-41   
The initial and peak D-dimer and NLR, in the 
survivors, are found significantly lower, as compared 
with the deceased. High NLR with lymphopenia 
suggests aggravated infection and is difficult to 
control.23 Present study findings of a lower count of 
lymphocytes and a higher count of neutrophils, with a 
high neutrophils-to-lymphocytes ratio (NLR) in the 
severely infected COVID-19 patients compared with 
the mildly infected group, are consistent with other 
studies.1,42-47 Age more than 50 years with an NLR of 
more than 3.13 predicts course towards a critical 
illness.43,48 In COVID-sepsis, neutrophils are hyper-
activated along with depletion of CD4 lymphocytes, as 
a result of apoptosis.40,49 Patients who died from 
COVID-19 are reported to have significantly lower 
lymphocytes count. This reflects exhausted adaptive 




1. Monitoring haematological and coagulation 
parameters might provide a reliable and 
convenient method for classifying and 
predicting the severity and outcomes of 
patients with COVID-19.  
2. High NLR and elevated D-dimer levels can be 
considered as independent risk factors in 
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